Sonoma Biotherapeutics Co-Founder Fred Ramsdell Awarded 2025 Nobel Prize in Physiology or Medicine for Pioneering FOXP3 Discovery and Advancing Treg Immunotherapy Sonoma Biotherapeutics, Inc., a leading clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for autoimmune…
Ignota Labs Strengthens Clinical Portfolio Through Acquisition of Kronos’s Development-Stage Assets Ignota Labs, an emerging pioneer in artificial intelligence–driven drug redevelopment, has announced the strategic acquisition of Kronos’s former clinical assets—istisociclib, a cyclin-dependent kinase 9 (CDK9) inhibitor, and entospletinib and…
Automated Cell Processing System Market Forecasts Set for Robust Growth Through 2035 Amid Rising Demand for Cell Therapies Automated Cell Processing System Market Industry Trends and Global Forecasts to 2035: Distribution by Cell Therapy Processing Step, Scale of Operation, End…
BUILT Biotechnologies Named Anchor Company at Commonwealth BioAccelerator, Scaling DNA Manufacturing-as-a-Service to Meet Surging Demand BUILT Biotechnologies,a rapidly emerging leader in DNA Manufacturing-as-a-Service, has announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative spearheaded by CvilleBioHub…
Global Molecular Diagnostics Market Set to Reach $30.9 Billion by 2035: Industry Trends, Technologies, and Key Players Molecular Diagnostics Market Industry Trends and Global Forecasts to 2035: Distribution by Test Type, Type of Offering, Type of Sample, Type of Technology,…
Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company committed to advancing innovative therapies for neurodegenerative diseases, today announced the pricing of its oversubscribed…
LEO Pharma a leading global company in medical dermatology LEO Pharma, a leading global company in medical dermatology, has successfully finalized its acquisition of Spevigo® from Boehringer Ingelheim, as officially announced on July 14, 2025. The transaction was completed following…
FIRE1’s Norm System and Congestion Score Highlighted as Late-Breaking Science at HFSA 2025 FIRE1, a pioneering company in connected medical device solutions, has announced that its innovative heart failure management program, encompassing the FUTURE-HF and FUTURE-HF2 trials, has been selected…
Endeavor BioMedicines Reports Positive Phase 2a Results for Taladegib in Idiopathic Pulmonary Fibrosis, Published in The Lancet Respiratory Medicine Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company focused on developing transformative therapies for life-threatening diseases, has announced the publication of Phase…
Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran). Vutrisiran…
Balchem Kicks Off New Era of Consumer Engagement: Showcasing the Power of Vitamin K2 at FC Bayern Women’s Season Opener When tens of thousands of fans poured into Munich’s Allianz Arena on September 6 for the opening match of the…
Bayer Canada Partners with Mint Pharmaceuticals to Enhance Access to ADALAT® XL 30 mg Tablets Across the Country Bayer Canada has announced a significant new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL 30 mg tablets throughout…